Article
Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach.
The pharmacogenomics journal - 23 Apr 2025
Nkya Siana, Nzunda Collin, Saukiwa Emmanuel, Kaywanga Frida, Buchard Eliud, Solomon David, Christopher Heavenlight, Ngowi Doreen, Johansen Julieth, Urio Florence, Mgaya Josephine, Kindole Christina, Yonazi Mbonea, Karim Salman, Alimohamed Mohamed Zahir, Sangeda Raphael Z, Chamba Clara, Dandara Collet, Novelli Enrico, Chimusa Emile R, Makani Julie
Abstract excerpt
In sub-Saharan Africa, sickle cell disease (SCD) remains a significant public health challenge. Despite the discovery of SCD over a century ago, progress in developing and accessing effective treatments has been limited. Hydroxyurea is the primary drug used for managing SCD and associated with improving clinical outcomes. However, up to 30% of patients do not respond to hydroxyurea, likely due to genetic factors....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.